ORCHID PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,148 INR | +2.65% |
|
-0.38% | +60.83% |
| Jun. 28 | Orchid Pharma Partners with Cipla to Launch Antibiotic Cefepime- Enmetazobactam in India | CI |
| Jun. 06 | Orchid Pharma Gets Indian Regulator's Nod for Enmetazobactam | MT |
| Sales 2024 | 8.19B 98.13M | Sales 2025 * | 10.28B 123M | Capitalization | 57.81B 692M |
|---|---|---|---|---|---|
| Net income 2024 | 922M 11.04M | Net income 2025 * | 1.49B 17.8M | EV / Sales 2024 | 6.31 x |
| Net cash position 2024 | 1.32B 15.82M | Net cash position 2025 * | 1.65B 19.74M | EV / Sales 2025 * | 5.46 x |
| P/E ratio 2024 |
72.1
x | P/E ratio 2025 * |
38.6
x | Employees | 838 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 28.94% |
More Fundamentals
* Assessed data
More news
Latest transcript on Orchid Pharma Limited
More press releases
| 1 day | +2.65% | ||
| 1 week | -0.38% | ||
| Current month | +0.70% | ||
| 1 month | +8.65% | ||
| 3 months | +4.85% | ||
| 6 months | +53.98% | ||
| Current year | +60.83% |
1 week
1 110.45
1 160.00
1 month
1 050.051 255.05
Current year
702.301 358.80
1 year
432.351 358.80
3 years
260.201 358.80
5 years
17.152 680.00
10 years
17.152 680.00
| Managers | Title | Age | Since |
|---|---|---|---|
Manish Dhanuka
CEO | Chief Executive Officer | 56 | 20-03-30 |
| Director of Finance/CFO | - | 20-06-28 | |
Kapil Dayya
CMP | Compliance Officer | - | Dec. 15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-03-30 | |
Mridul Dhanuka
BRD | Director/Board Member | 42 | 20-03-30 |
Manish Dhanuka
CEO | Chief Executive Officer | 56 | 20-03-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 1,148 | +2.65% | 4,048 |
| 24-07-15 | 1,118 | -1.03% | 4,043 |
| 24-07-12 | 1,130 | -2.08% | 4,188 |
| 24-07-11 | 1,154 | +1.17% | 1,722 |
| 24-07-10 | 1,141 | -1.01% | 4,457 |
Delayed Quote Bombay S.E., July 16, 2024 at 06:00 am EDT
More quotes
Orchid Pharma Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of integrated active pharmaceutical ingredients (API). It operates through the pharmaceutical segment. It has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. It offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,140
INR
Average target price
1,252
INR
Spread / Average Target
+9.87%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 856B | |
| +38.95% | 631B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +9.18% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B |
- Stock Market
- Equities
- ORCHPHARMA Stock
- ORCHPHARMA Stock
